In the first study, Tammiste et al. in 2013 conducted a small (n = 10) exome wide association study of treatment non-response in MDD and found variants in bone morphogenetic protein 5 (BMP5) to be associated with non-response to a single treatment trial of escitalopram60. Here, BMP5 is linked to major depressive disorder.